Advice
Following a full submission.
Etanercept (Enbrel®) is accepted for use within NHS Scotland for the treatment of active and progressive psoriatic arthritis in adults. It is the first drug to be licensed for this indication and not only improves symptoms of arthritis and psoriasis, but may slow the progression of joint damage (at least over a period of one year).
Download detailed advice44KB (PDF)
Medicine details
- Medicine name:
- Etanercept (Enbrel®)
- SMC ID:
- 107/04
- Indication:
- Psoriatic arthritis
- Pharmaceutical company
- Wyeth Pharmaceuticals
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 12 July 2004